Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.
Study Identifier:
ACH443-006
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other
Study Details
Medical Condition
- Human Immunodeficiency Virus
Study Drug
- Drug: ACH126-443 (Beta-L-Fd4C)
Date
N/A - N/A
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Human Immunodeficiency Virus
Study Drug
- Drug: ACH126-443 (Beta-L-Fd4C)
Date
N/A - N/A
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
To determine safety and efficacy of ACH-126,443 on the treatment of adults with HIV infection who have modestly detectable viral load while on stable triple combination antiretroviral therapy including 3TC.
Trial Locations
Location
Status
Location
Body Positive, Inc.
Phoenix, Arizona, United States, 85006
Status
N/A
Location
L.a., California, United States
Status
N/A
Location
Pacific Horizon Medical Group, Inc.
San Francisco, California, United States, 94115
Status
N/A
Location
Community Health Care Center One, Inc.
Ft. Lauderdale, Florida, United States, 33306
Status
N/A
Location
South Shore Hospital
Miami Beach, Florida, United States, 33160
Status
N/A
Location
AIDS Research Consortium
Atlanta, Georgia, United States, 30308
Status
N/A